NightstaRx closes $45mm Series C round

15:40 EDT 30 Jun 2017 | Elsevier Business Intelligence

NightstaRx Ltd. (gene therapies for inherited retinal diseases) raised $45mm in its Series C financing to first-time backers ...

Original Article: NightstaRx closes $45mm Series C round


More From BioPortfolio on "NightstaRx closes $45mm Series C round"

Quick Search


Relevant Topics

Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Muscular Dystrophy
Muscular dystrophy is a group of degenerative inherited disorders causing muscle weakness and loss of muscle tissue. The different types are Becker muscular dystrophy, Duchenne muscular dystrophy, Emery-Dreifuss muscular dystrophy, Facioscapulohumeral mu...